FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
暂无分享,去创建一个
J. Taïeb | J. Spano | J. Taieb | B. Landi | T. Aparicio | G. Lledo | P. Artru | T. Lecomte | J. Desramé | T. Mansourbakht | A. Asnacios | D. Fallik | Amani Asnacios | Jean-Philippe Spano
[1] A. de Gramont,et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients , 2006, British Journal of Cancer.
[2] P. Maisonneuve,et al. Epidemiology and risk factors for pancreatic cancer. , 2006, Best practice & research. Clinical gastroenterology.
[3] J. Neoptolemos,et al. PHASE III RANDOMISED COMPARISON OF GEMCITABINE (GEM) WITH GEMCITABINE PLUS CAPECITABINE (GEM-CAP) IN PATIENTS WITH ADVANCED PANCREATIC CANCER , 2005 .
[4] A. Dachman,et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. V. Von Hoff,et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] E. Felekouras,et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study , 2005, Investigational New Drugs.
[7] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Conroy,et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Miller,et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Wolff,et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Van Cutsem,et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. de Gramont,et al. Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer , 2003, American journal of clinical oncology.
[13] W. Scheithauer,et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma , 2003, British Journal of Cancer.
[14] R. Klapdor,et al. Sequential polychemotherapy in exocrine pancreatic cancer. , 2003, Anticancer research.
[15] M. Dimopoulos,et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] M. Kornmann,et al. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[17] W. Scheithauer,et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Daniel G Haller,et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Hickish,et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Nemunaitis,et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer , 2002, British Journal of Cancer.
[21] J. Hainsworth,et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Colucci,et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma , 2002, Cancer.
[23] P. Homel,et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. , 2001, The oncologist.
[24] R. Danesi,et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Klapdor,et al. Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. , 2000, Anticancer research.
[26] H. Oettle,et al. The role of gemcitabine alone and in combination in the treatment of pancreatic cancer , 2000, Anti-cancer drugs.
[27] V. Heinemann,et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[29] G. Peters,et al. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. , 1999, European journal of cancer.
[30] D. Forman,et al. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group. , 1998, European journal of cancer.
[31] C. Erlichman,et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity , 1998, Cancer Chemotherapy and Pharmacology.
[32] S. Guichard,et al. Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo , 1997 .
[33] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Linné,et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] P. Vrignaud,et al. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice , 1996, Anti-cancer drugs.
[36] F. Baas,et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] H. Tomoda,et al. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. , 1995, Anti-cancer drugs.
[38] J. Verweij,et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] C. la Vecchia,et al. Trends in pancreatic cancer mortality in Europe, 1955–1989 , 1994, International journal of cancer.
[40] T. Taguchi,et al. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.
[41] J. Pignon,et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] T. Shimazoe,et al. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay. , 1992, Biochemical and biophysical research communications.
[43] R. Simon,et al. How large should a phase II trial of a new drug be? , 1987, Cancer treatment reports.